<DOC>
	<DOCNO>NCT02787239</DOCNO>
	<brief_summary>Multicenter , Randomized , Double-blind , Parallel , Phase III Clinical Study Compare Efficacy Safety Rituximab Biosimilar HLX01 MabThera Combination With CHOP , Previously Untreated Subjects With CD20+ DLBCL</brief_summary>
	<brief_title>Clinical Study Compare Efficacy Safety Rituximab Biosimilar HLX01 Rituximab Combination With CHOP , Previously Untreated Subjects With CD20+ DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Untreated CD20positive DLBCL confirm . IPI score 1 2 , Stage I ~ IV , Score 0 need accompany bulky disease , define presence tumor mass diameter 7.5 cm . ECOG performance status 0 2 . More 6 month life expectancy . At least one measurable lesion : For nodal tumor mass , 1.5 cm long axis 1.0 cm short axis ; For extranodal tumor mass , 1.0 cm long axis . 18 year 70 year ; Male female patient . Known allergic reaction human murine monoclonal antibody , murine product , foreign protein . Known allergic reaction component CHOP regimen . Previous treatment NHL , include chemotherapy , immunotherapy , partial radiotherapy lymphoma , monoclonal antibody therapy surgical treatment ( exclude lymph node biopsy surgical resection nonlymphoma lesion ) . History cytotoxic drug treatment antiCD20 monoclonal antibody treatment disease ( e.g. , rheumatoid arthritis ) . Prior use monoclonal antibody within 3 month . Primary central nervous system ( CNS ) lymphoma , secondary CNS involvement , grey zone lymphoma ( GZL ) burkitt DLBCL , primary effusion lymphoma , plasmablastic lymphoma , primary cutaneous DLBCL , anaplastic lymphoma kinase ( ALK ) positive DLBCL transform lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>